Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year ...
The FDA today expanded the approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) to men with metastatic prostate cancer that has not been treated with androgen pathway dru ...
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
One of the most discussed use cases in pharma and biotech for AI is the creation of digital twins. By using massive amounts ...
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and ...
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while ...
ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and ...
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim ...
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
METiS TechBio announced a strategic collaboration with Eli Lilly and Company focused on researching and discovering novel lipid nanoparticle (LNP)-based delivery solutions designed to enable ...
The FDA today approved a subcutaneous induction regimen for AbbVie's Skyrizi (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease. 1 The decision lets patients start ...
Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results